Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics, Viking Therapeutics emerges as a potential takeover target due to its promising weight-loss drug pipeline, particularly VK2735 in phase 3 trials. The anti-obesity market is projected to reach $190 billion by 2035, making it attractive for pharmaceutical giants seeking to acquire proven candidates rather than develop from scratch. However, Viking's stock carries significant risk tied to upcoming phase 3 data readouts.

07/30/2026, 6:30 PM • The Motley Fool

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."

Wall Street analysts are bullish on Viking Therapeutics (VKTX), with a consensus price target of $91 representing a potential 150% return. The optimism centers on VK2735, a dual-formulation weight-loss drug showing promising phase 2 efficacy data. However, key phase 3 results won't arrive until late 2027-2028, and some phase 2 oral trial tolerability concerns exist. Cautious investors may want to wait for upcoming maintenance trial results before investing.

07/18/2026, 9:30 AM • The Motley Fool

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Viking Therapeutics breached fiduciary duties to shareholders through potential self-dealing. The firm is seeking long-term VKTX stockholders to participate in shareholder litigation, offering free consultations with no obligation.

07/16/2026, 9:31 PM • GlobeNewswire

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Rhythm Pharmaceuticals breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is also investigating similar matters at Travere Therapeutics and Viking Therapeutics.

07/16/2026, 9:16 PM • GlobeNewswire

Is It Too Late to Buy Eli Lilly?

Eli Lilly stock has surged 400% over five years, driven by dominance in the GLP-1 weight loss drug market with products like Mounjaro and Zepbound generating over $12 billion in recent quarterly sales. Despite the stock's significant gains and current $1,200+ price, analysts suggest it remains reasonably valued with strong growth prospects from its oral drug Foundayo and promising pipeline candidate retatrutide, making it still worth considering for investors.

07/08/2026, 2:10 PM • The Motley Fool

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.

07/06/2026, 7:35 AM • The Motley Fool

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

Viking Therapeutics' lead drug candidate VK2735, a dual GLP-1/GIP agonist, shows promise in the competitive weight-loss market with potential for rapid weight loss via injectable form followed by oral maintenance. However, the company faces significant risks including safety concerns from phase 2 trials, long development timelines (phase 3 results not expected until 2027-2028), and likely acquisition by a larger pharmaceutical company if successful.

07/06/2026, 7:15 AM • The Motley Fool

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Viking Therapeutics' obesity drug candidate VK2735 could potentially grow a $1,000 investment to $2,500-$3,400 by 2030 under favorable conditions, but faces significant competition from established players Eli Lilly and Novo Nordisk. The company will likely need to dilute shares through fundraising, and the drug must capture at least 1% market share to justify current valuations. Clinical trial failure could reduce investments by 60-80%.

07/05/2026, 1:05 AM • The Motley Fool

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying

Viking Therapeutics, a $4.3B biotech company, is developing VK2735, a weight loss drug candidate in late-stage trials. Bulls cite the massive $100B obesity drug market opportunity, potential acquisition interest, and positive historical stock reactions to data releases. Bears highlight competition from pharma giants Eli Lilly and Novo Nordisk, pipeline risk, and the stock's 40% year-over-year gain. The analyst believes the bull case outweighs the bear case, suggesting Viking could reach $50 if upcoming data proves positive.

07/04/2026, 5:10 AM • The Motley Fool

Here's Why Viking Therapeutics Stock Surged Higher in June

Viking Therapeutics stock rose 19.2% in June driven by optimism over its weight-loss drug pipeline, particularly VK2735, a GLP-1/GIP agonist showing steeper weight loss rates than competitors. The company also initiated a Phase 1 trial for VK3019, a new class of weight-loss drug with a different mechanism. Investors await Phase 3 trial results expected in 2027-2028 and Phase 1 maintenance trial results in Q3 2026.

07/03/2026, 9:25 AM • The Motley Fool

Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy?

Eli Lilly stock reached a new all-time high, driven by its blockbuster weight loss treatment. The company holds dominant market share in the weight loss drug category and is being positioned as a clear winner in the GLP-1 drug space, with analysts highlighting its strong performance at industry conferences.

06/26/2026, 8:15 PM • The Motley Fool

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recommends Viking due to the substantially larger market opportunity in obesity treatment, despite competitive pressures from industry giants like Eli Lilly and Novo Nordisk.

06/26/2026, 11:05 AM • The Motley Fool

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

The GLP-1 drug market is projected to reach $185 billion by 2033. Eli Lilly dominates with its successful Mounjaro and Zepbound drugs generating $13 billion in Q1 revenue, but trades at a premium 39x earnings. Viking Therapeutics, a smaller biotech with no approved products yet, offers higher risk/reward potential with its promising VK2735 candidate in phase 3 trials. The author recommends Viking as the better buy for risk-tolerant investors seeking significant upside.

06/23/2026, 10:14 AM • The Motley Fool

Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 Years

The article recommends Amazon and Costco as long-term 'set and forget' stocks suitable for 20-year holding periods. Amazon benefits from its dominance in e-commerce and cloud computing (AWS), which is experiencing explosive growth from the AI boom. Costco's membership-based model with high renewal rates (92% in U.S./Canada) and low-margin warehouse sales offset by high-margin membership fees provide stability across market conditions.

06/22/2026, 11:20 AM • The Motley Fool

Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics, a biotech company developing weight loss drug candidates, could potentially reach $100 per share according to Wall Street analysts, though it currently trades around $27. The company's lead candidate VK2735, a dual GLP-1/GIP receptor agonist, is in late-stage trials and would be the first dual GLP-1/GIP drug available in oral format. Upcoming catalysts include maintenance dosing study data in Q3 and a phase 3 trial launch for the oral version in Q4. While a jump to $100 would require a 200%+ increase, positive trial results and market momentum could drive the stock higher in coming quarters.

06/12/2026, 1:15 AM • The Motley Fool